Alzinova AB (SE0007413455)
XSTU 
XSTO Primary XSTU Summary
SE0007413455 Chart
Alzinova AB (SE0007413455) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alzinova AB ever had a stock split?
Alzinova AB Profile
| Biotechnology Industry | Healthcare Sector | Dr. Tord Labuda M.Sc., Ph.D. CEO | XSTU Exchange | SE0007413455 ISIN |
| SE Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alzinova AB (publ) is a Sweden-based biopharmaceutical company dedicated to the fight against Alzheimer's disease via the development of an active immunotherapy. Founded in 2011 and headquartered in Mölndal, Sweden, the company emerges as a key player in the quest for effective treatments for Alzheimer's disease. Leveraging scientific innovation, Alzinova focuses on addressing the unmet needs within the Alzheimer's treatment landscape, emphasizing the development of specific and potentially groundbreaking therapeutic options.
Products and Services
- ALZ-101
The flagship product of Alzinova AB, ALZ-101, represents a pioneering approach in Alzheimer's disease treatment. It is an oligomer-specific vaccine aimed at targeting and neutralizing oligomers, which are known to be toxic aggregates contributing to the progression of Alzheimer's disease. This vaccine is in development as a preventive and therapeutic option, embodying the company’s commitment to innovating Alzheimer's disease treatment methodologies.
- ALZ-201
Expanding its portfolio of solutions against Alzheimer's, Alzinova is also developing ALZ-201, a monoclonal antibody designed to neutralize the toxic oligomers associated with the disease. Similar to ALZ-101, ALZ-201 focuses on a critical aspect of Alzheimer’s pathology. The development of this monoclonal antibody showcases Alzinova's dedication to offering diverse therapeutic avenues tailored towards halting or slowing the disease's progression through targeted intervention.
